Real-world outcomes, treatment patterns and T790M testing rates in Non-Small Cell Lung Cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT: Outcomes and treatments of EGFR-mutated NSCLC patients from Slovenia. Radiology and Oncology, v. 56, n. 3, p. 371–379, 8 Sep.2022.